Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.

MLA

Loriot, Yohann, et al. “Enzalutamide in Castration-Resistant Prostate Cancer Patients with Visceral Disease in the Liver and/or Lung: Outcomes from the Randomized Controlled Phase 3 AFFIRM Trial.” Cancer (0008543X), vol. 123, no. 2, Jan. 2017, pp. 253–62. EBSCOhost, https://doi.org/10.1002/cncr.30336.

APA

Loriot, Y., Fizazi, K., Bono, J. S., Forer, D., Hirmand, M., Scher, H. I., & de Bono, J. S. (2017). Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer (0008543X), 123(2), 253–262. https://doi.org/10.1002/cncr.30336

Chicago

Loriot, Yohann, Karim Fizazi, Johann S. Bono, David Forer, Mohammad Hirmand, Howard I. Scher, and Johann S de Bono. 2017. “Enzalutamide in Castration-Resistant Prostate Cancer Patients with Visceral Disease in the Liver and/or Lung: Outcomes from the Randomized Controlled Phase 3 AFFIRM Trial.” Cancer (0008543X) 123 (2): 253–62. doi:10.1002/cncr.30336.